BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Mediterr J Hematol Infect Dis [Internet]. 2016 Feb. 10 [cited 2026 May 12];8:e2016011. Available from: https://www.mjhid.org/mjhid/article/view/2016.011